SNY - Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients
Aimmune Therapeutics' (NASDAQ: AIMT) share price has gained 11% over the past month as the company waits for the Food and Drug Administration to issue an approval decision on its very first drug, one that represents the theme of its three-drug pipeline: treatments to address food allergies.
The decision on Palforzia, an immunotherapy for peanut allergy in children and teens, is expected by Jan. 17. Investors are feeling optimistic because an FDA advisory committee offered a favorable opinion on the drug in September. While the FDA doesn't have to follow the committee's move, it does take the opinion into consideration.
Image source: Getty Images.